{
    "hands_on_practices": [
        {
            "introduction": "A central achievement of the modern palliative care movement was the application of scientific principles to the art of symptom management. To ensure patient safety and consistent pain relief when switching between different opioid medications, clinicians developed standardized frameworks. This practice introduces the foundational concept of Morphine Milligram Equivalents (MME), a system for quantifying a patient's total daily opioid exposure against a common reference, oral morphine. Mastering this calculation is a key step in understanding the pharmacological precision that underpins effective and safe palliative medicine. ",
            "id": "4775356",
            "problem": "In the late twentieth century, as the modern hospice movement took shape and palliative care matured into a specialized field, clinicians increasingly relied on equianalgesic frameworks to standardize opioid exposure across different agents. A common operationalization is Morphine Milligram Equivalents (MME), which represents the total daily opioid exposure expressed as the dose of oral morphine that would be considered equianalgesic, using opioid-specific conversion factors derived from consensus tables and clinical studies.\n\nA patient in a hospice program is prescribed oral oxycodone, $10$ mg every $6$ hours. For this historical-epidemiologic standardization exercise, adopt a conversion factor of $1.5$ from oral oxycodone to oral morphine in terms of MME. Using the equianalgesic standardization concept described above, determine the total daily MME for this regimen.\n\nExpress your final result as a single real-valued number representing milligrams morphine equivalent per day (mg MME/day). Do not include units in your final numeric answer. No rounding is required.",
            "solution": "The problem requires the calculation of the total daily Morphine Milligram Equivalents (MME) for a patient receiving a specific regimen of oral oxycodone. The validation of the problem statement is the first procedural step.\n\n### Step 1: Extract Givens\n-   Medication: oral oxycodone\n-   Dose per administration: $10$ mg\n-   Frequency of administration: every $6$ hours\n-   Conversion factor from oral oxycodone to oral morphine: $1.5$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria.\n-   **Scientifically Grounded**: The concept of Morphine Milligram Equivalents (MME) and the use of conversion factors are standard, evidence-based practices in clinical pharmacology and pain management. The conversion factor of $1.5$ for oral oxycodone to oral morphine is a commonly cited value, though it may vary slightly across different clinical guidelines (e.g., the CDC cites this value). The problem is based on established clinical and pharmacological principles.\n-   **Well-Posed**: The problem provides all necessary data (dose, frequency, conversion factor) to compute a single, unique numerical answer for the total daily MME. The objective is clearly stated.\n-   **Objective**: The problem is stated in precise, objective language, free of subjective claims or bias. The clinical scenario is described factually.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. The data are consistent and the scenario is clinically plausible. Therefore, the problem is deemed valid.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution Derivation\nLet $D_{oxy, single}$ be the single dose of oral oxycodone, $T$ be the interval between doses, and $C_{oxy \\to mor}$ be the conversion factor from oral oxycodone to oral morphine equivalent.\n\nThe given values are:\n-   $D_{oxy, single} = 10 \\text{ mg}$\n-   $T = 6 \\text{ hours}$\n-   $C_{oxy \\to mor} = 1.5$ (dimensionless in this context, but represents mg MME per mg of oral oxycodone)\n\nThe first step is to calculate the total daily dose of oral oxycodone, denoted as $D_{oxy, total}$. A day consists of $24$ hours. The number of doses administered per day, $n$, can be calculated as:\n$$n = \\frac{24 \\text{ hours/day}}{T} = \\frac{24 \\text{ hours/day}}{6 \\text{ hours/dose}} = 4 \\text{ doses/day}$$\n\nThe total daily dose of oral oxycodone is the product of the single dose and the number of doses per day:\n$$D_{oxy, total} = D_{oxy, single} \\times n$$\n$$D_{oxy, total} = 10 \\text{ mg/dose} \\times 4 \\text{ doses/day} = 40 \\text{ mg/day}$$\n\nThe second step is to convert this total daily dose of oral oxycodone into Morphine Milligram Equivalents (MME). Let $MME_{total}$ represent the total daily MME. This is calculated by multiplying the total daily dose of oral oxycodone by the given conversion factor:\n$$MME_{total} = D_{oxy, total} \\times C_{oxy \\to mor}$$\n\nSubstituting the calculated and given values:\n$$MME_{total} = 40 \\text{ mg/day} \\times 1.5$$\n$$MME_{total} = 60 \\text{ mg MME/day}$$\n\nThe total daily MME for this regimen is $60$. The problem asks for a single real-valued number representing this quantity.",
            "answer": "$$\\boxed{60}$$"
        },
        {
            "introduction": "The ethical commitment to relieve suffering lies at the heart of the hospice philosophy, but this commitment often involves complex decisions where benefits and risks must be carefully weighed. Using potent medications like opioids to ease severe symptoms such as dyspnea (shortness of breath) is a cornerstone of palliative care, yet it requires rigorous ethical justification. This exercise asks you to apply the Principle of Double Effect, a key ethical framework used to distinguish between an intended good outcome (symptom relief) and a foreseen but unintended potential harm, thereby clarifying the moral basis for compassionate end-of-life care. ",
            "id": "4775408",
            "problem": "A clinician at a community hospice, working in the tradition of the modern hospice movement established by Cicely Saunders, considers titrating opioid therapy for a patient with end-stage lung disease experiencing refractory dyspnea. The patient is on hospice, has capacity, and has consented to symptom-focused care aligned with comfort goals. The dyspnea is currently rated at $8$ on a Numeric Rating Scale (NRS) from $0$ to $10$, and evidence from prior similar patients suggests that an appropriately titrated opioid regimen would reduce dyspnea severity by approximately $50\\%$ within $24$ hours while increasing the estimated short-term risk of respiratory compromise from $5\\%$ to $8\\%$. The clinician does not intend sedation, and respiratory compromise is not used as a means to relieve dyspnea; it is a foreseen but unintended risk.\n\nUsing the Principle of Double Effect (PDE), which in palliative care and hospice practice requires that the nature of the act be good or neutral (e.g., symptom relief), that the agent intend the good effect (and not the bad), that the bad effect not be the means to the good, and that there be proportionate reason, evaluate whether the intervention is ethically justified. In defending your evaluation, begin from fundamental ethical principles (beneficence and non-maleficence) and a transparent, first-principles risk–benefit reasoning that compares expected symptom burden reduction with expected harm. Assume the NRS is an interval scale suitable for coarse expected burden calculations, and take respiratory compromise, if it occurs, to represent a high-severity adverse outcome on the same $0$ to $10$ scale.\n\nWhich option best captures whether the intervention is justified under the Principle of Double Effect and why?\n\nA. The intervention is not justified under the Principle of Double Effect because respiratory compromise is the mechanism by which opioids relieve dyspnea; therefore, the bad effect is used as a means to the good effect.\n\nB. The intervention is justified under the Principle of Double Effect because opioid titration for symptom relief is a good or neutral act, the clinician intends dyspnea relief (not harm), respiratory compromise is foreseen but not the means to the good effect, and proportionality holds: the expected reduction in dyspnea burden from a $50\\%$ decrease (from NRS $8$ to $4$) outweighs the absolute $3$-percentage-point increase in risk (from $5\\%$ to $8\\%$) of a high-severity adverse event.\n\nC. The intervention is not justified because any increase in risk violates non-maleficence; proportionality is irrelevant if risk increases at all.\n\nD. The intervention is justified only if the relative risk increase is less than $10\\%$; since the risk rises from $5\\%$ to $8\\%$, a relative increase of $60\\%$, the intervention is not justified.\n\nE. The intervention is not justified because the hospice movement historically discouraged opioid use for dyspnea due to respiratory risks, making such titration inconsistent with hospice ethics.",
            "solution": "The problem statement is critically evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Patient Condition**: End-stage lung disease with refractory dyspnea, currently rated at $8$ on a Numeric Rating Scale (NRS) from $0$ to $10$.\n- **Patient Status**: On hospice, has decision-making capacity, and has consented to symptom-focused care aligned with comfort goals.\n- **Intervention**: Titrating opioid therapy for dyspnea.\n- **Clinician's Intent**: The clinician does not intend sedation. Respiratory compromise is a foreseen but unintended risk and is not the means to relieve dyspnea.\n- **Expected Good Effect**: The opioid regimen is expected to reduce dyspnea severity by approximately $50\\%$ within $24$ hours.\n- **Expected Bad Effect**: The estimated short-term risk of respiratory compromise increases from $5\\%$ to $8\\%$.\n- **Ethical Framework**: The Principle of Double Effect (PDE) is to be used. The problem statement defines its four conditions:\n    1.  The nature of the act is good or neutral.\n    2.  The agent intends the good effect, not the bad effect.\n    3.  The bad effect is not the means to the good effect.\n    4.  There is a proportionate reason for the act.\n- **Analytical Assumptions**:\n    - The NRS is an interval scale.\n    - Respiratory compromise is a high-severity adverse outcome, representable on the same $0$ to $10$ scale.\n    - The evaluation must begin from the principles of beneficence and non-maleficence and use risk-benefit reasoning.\n- **Historical Context**: The clinician is working in the tradition of the modern hospice movement established by Cicely Saunders.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Groundedness**: The problem describes a standard clinical scenario in palliative medicine. The use of opioids for refractory dyspnea is an evidence-based practice. The known risk of respiratory depression (compromise) and the ethical framework of the Principle of Double Effect are central to end-of-life care decisions. The premise that opioids relieve dyspnea via central mechanisms rather than by causing respiratory depression is pharmacologically correct. The problem is factually and scientifically sound.\n- **Well-Posedness**: The problem is well-posed. It provides a specific clinical context, a clear ethical framework (PDE), and sufficient quantitative and qualitative data to allow for a reasoned analysis and conclusion. A unique answer can be derived by applying the stated principles to the given facts.\n- **Objectivity**: The problem is stated in objective, clinical language. It avoids subjective or emotionally charged terms and provides numerical data to guide a structured analysis.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically grounded, well-posed, objective, and internally consistent. It presents a classic ethical dilemma that can be formally analyzed using the provided framework. The solution process may proceed.\n\n### Solution Derivation\nThe task is to evaluate the ethical justification of the proposed opioid titration using the Principle of Double Effect (PDE) and its four conditions. The analysis will incorporate the principles of beneficence (acting for the patient's benefit) and non-maleficence (avoiding harm), operationalized through a risk-benefit calculation as requested.\n\n1.  **Nature of the Act**: The act is the administration of opioid medication with the goal of relieving a distressing symptom (refractory dyspnea). Relieving suffering is a fundamental goal of medicine and an expression of the principle of beneficence. The act of administering a medication is, in itself, ethically neutral. Therefore, this condition is satisfied.\n\n2.  **Intention**: The problem explicitly states, \"The clinician does not intend sedation, and respiratory compromise is not used as a means...it is a foreseen but unintended risk.\" The clinician's sole intention is the good effect: relief of dyspnea. The bad effect (respiratory compromise) is foreseen but not desired. This satisfies the second condition of PDE.\n\n3.  **Means-End**: The bad effect must not be the means to achieve the good effect. The problem states, \"respiratory compromise is not used as a means to relieve dyspnea.\" This is consistent with the pharmacology of opioids for dyspnea, which act primarily on central nervous system receptors to reduce the perception of breathlessness, an effect distinct from respiratory depression. Therefore, the good effect (dyspnea relief) is a direct result of the medication's therapeutic action, while the bad effect (respiratory compromise) is an unwanted side effect. This condition is satisfied.\n\n4.  **Proportionality**: The good effect must be proportionate to the foreseen bad effect. This requires a risk-benefit analysis, comparing the expected benefit with the expected harm.\n\n    - **Expected Benefit (Reduction in Symptom Burden)**: The patient's dyspnea is at a severity of $8$ on a $0$-$10$ NRS. The intervention is expected to reduce this by $50\\%$.\n    $$ \\text{Initial Burden} = 8 \\text{ points} $$\n    $$ \\text{Expected Reduction} = 50\\% \\times 8 = 0.5 \\times 8 = 4 \\text{ points} $$\n    $$ \\text{Final Burden} = 8 - 4 = 4 \\text{ points} $$\n    The expected benefit is a reduction in suffering equivalent to $4$ points on the NRS. For a patient with end-stage disease and refractory symptoms, this is a very significant improvement in quality of life.\n\n    - **Additional Expected Harm (Risk of Respiratory Compromise)**: The problem defines respiratory compromise as a \"high-severity adverse outcome.\" To perform a conservative, worst-case analysis, we can assign it the maximum severity on the same scale, which is $10$. The risk of this event increases due to the intervention.\n    $$ \\text{Risk without intervention} = P_{\\text{initial}} = 5\\% = 0.05 $$\n    $$ \\text{Risk with intervention} = P_{\\text{final}} = 8\\% = 0.08 $$\n    The absolute increase in risk is:\n    $$ \\Delta P = P_{\\text{final}} - P_{\\text{initial}} = 0.08 - 0.05 = 0.03 \\text{ or } 3\\% $$\n    The *additional* expected harm is the increase in probability multiplied by the severity of the harm.\n    $$ \\text{Additional Expected Harm} = \\Delta P \\times \\text{Severity} = 0.03 \\times 10 = 0.3 \\text{ points} $$\n\n    - **Comparison**: We compare the magnitude of the expected benefit to the magnitude of the additional expected harm.\n    $$ \\text{Expected Benefit} = 4 \\text{ points} $$\n    $$ \\text{Additional Expected Harm} = 0.3 \\text{ points} $$\n    Since $4 \\gg 0.3$, the expected benefit of substantially relieving severe, refractory dyspnea is vastly greater than the additional expected harm from the small increase in the risk of respiratory compromise. The proportionality condition is strongly satisfied.\n\n**Conclusion**: All four conditions of the Principle of Double Effect are met. The intervention is ethically justified.\n\n### Option-by-Option Analysis\n\n**A. The intervention is not justified under the Principle of Double Effect because respiratory compromise is the mechanism by which opioids relieve dyspnea; therefore, the bad effect is used as a means to the good effect.**\nThis statement is factually incorrect regarding pharmacology and directly contradicts the problem's explicit premise that \"respiratory compromise is not used as a means to relieve dyspnea.\" It incorrectly assesses the third condition of PDE (Means-End).\n**Verdict: Incorrect.**\n\n**B. The intervention is justified under the Principle of Double Effect because opioid titration for symptom relief is a good or neutral act, the clinician intends dyspnea relief (not harm), respiratory compromise is foreseen but not the means to the good effect, and proportionality holds: the expected reduction in dyspnea burden from a $50\\%$ decrease (from NRS $8$ to $4$) outweighs the absolute $3$-percentage-point increase in risk (from $5\\%$ to $8\\%$) of a high-severity adverse event.**\nThis option correctly identifies that all four conditions of PDE are met. It accurately summarizes the nature of the act, the clinician's intent, the means-end distinction, and the principle of proportionality. The reasoning that the significant symptom relief (from an NRS of $8$ to $4$) for a suffering patient outweighs the modest absolute increase in risk ($3$ percentage points) is sound and aligns with the quantitative analysis above.\n**Verdict: Correct.**\n\n**C. The intervention is not justified because any increase in risk violates non-maleficence; proportionality is irrelevant if risk increases at all.**\nThis posits an absolutist view of non-maleficence (\"do no harm\") that is incompatible with virtually all medical practice, as nearly every effective intervention carries some risk. The Principle of Double Effect is specifically designed to navigate situations where harm is a possible, foreseen side effect of a beneficial action. This option dismisses the core concept of proportionality, which is essential to both the PDE and modern medical ethics.\n**Verdict: Incorrect.**\n\n**D. The intervention is justified only if the relative risk increase is less than $10\\%$; since the risk rises from $5\\%$ to $8\\%$, a relative increase of $60\\%$, the intervention is not justified.**\nThis option introduces an arbitrary and non-standard ethical rule based on relative risk increase. The PDE's proportionality condition does not use such a threshold. Ethical analysis requires weighing the absolute benefit against the absolute increase in risk and the severity of the potential harm. The relative risk can be misleading; a $60\\%$ increase on a tiny baseline risk could be acceptable, while a $10\\%$ increase on a high baseline risk might not. The calculation is correct ($\\frac{8-5}{5} = 0.6 = 60\\%$), but its application as a rigid ethical rule is invalid.\n**Verdict: Incorrect.**\n\n**E. The intervention is not justified because the hospice movement historically discouraged opioid use for dyspnea due to respiratory risks, making such titration inconsistent with hospice ethics.**\nThis is a historically inaccurate claim. Dame Cicely Saunders, the founder of the modern hospice movement, was a key figure in promoting the liberal and appropriate use of opioids to control severe symptoms, including pain and dyspnea, at the end of life. The careful titration of opioids for symptom management is a cornerstone of modern hospice and palliative care philosophy, not a violation of it.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The transition of hospice from a philanthropic movement to an integrated part of the healthcare landscape depended on the creation of stable administrative and financial structures. In the United States, the establishment of the Medicare Hospice Benefit (MHB) in 1982 was the single most important development in this process, defining eligibility, coverage, and the rules of access. This problem provides a hands-on look at the real-world application of these regulations. By analyzing a patient's journey through election, revocation, and re-election of the benefit, you will gain insight into the systemic framework that governs how patients access hospice care. ",
            "id": "4775427",
            "problem": "A patient with metastatic pancreatic cancer elects the Medicare hospice benefit (MHB) administered by the Centers for Medicare & Medicaid Services (CMS). The MHB was introduced in $1982$ and organizes coverage into consecutive benefit periods to support periodic reassessment of terminal status: two initial $90$-day periods followed by an unlimited series of $60$-day periods, each requiring physician certification of a prognosis of $6$ months or less at the start of the period. After approximately $2$ months (about $60$ days) in hospice, the patient revokes the election to pursue disease-directed therapy. Three months later, the patient’s condition declines and they re-elect hospice. Based on the foundational structure of benefit periods and the definitions of election, revocation, and re-election, which statement best describes what happens to the patient’s benefit periods upon re-election?\n\nA. Upon re-election, the patient resumes the unused days of the first $90$-day benefit period and completes the remaining portion before moving to the second $90$-day period.\n\nB. Upon re-election, the patient begins the second $90$-day benefit period because the first $90$-day period was consumed by the initial election even though it was only partially used.\n\nC. Revocation resets the MHB entirely, allowing the patient to start over at the first $90$-day benefit period upon re-election.\n\nD. The patient must wait for the remaining days of the first $90$-day period to elapse (outside hospice) before re-electing, at which point they start the second $90$-day period.\n\nE. Upon re-election, the patient skips directly to the $60$-day periods because any revocation automatically bypasses the second $90$-day period.",
            "solution": "The user has provided a problem concerning the rules of the Medicare Hospice Benefit (MHB) and asks for the consequence of a patient's revocation and subsequent re-election.\n\n### Step 1: Extract Givens\n-   **Program:** Medicare Hospice Benefit (MHB), administered by the Centers for Medicare & Medicaid Services (CMS).\n-   **Introduction Year:** `$1982$`.\n-   **Benefit Period Structure:** A sequence of consecutive benefit periods, consisting of two initial `$90$`-day periods, followed by an unlimited series of `$60$`-day periods.\n-   **Eligibility:** Each benefit period requires a physician certification of a prognosis of `$6$` months or less.\n-   **Patient Scenario:**\n    1.  A patient elects the MHB, starting the first benefit period.\n    2.  The patient stays in hospice for approximately `$2$` months (about `$60$` days).\n    3.  The patient revokes the MHB election.\n    4.  The patient remains outside of hospice for `$3$` months.\n    5.  The patient re-elects the MHB.\n-   **Question:** What happens to the patient's benefit periods upon re-election?\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement describes a real-world administrative and regulatory system, the Medicare Hospice Benefit. The structure of the benefit periods (90-90-60-60-...) and the concepts of election, revocation, and re-election are factually correct as per CMS regulations (42 C.F.R. Part 418). The scenario presented is clinically plausible and poses a question that can be answered through logical application of the system's rules.\n\n-   **Scientifically Grounded:** The problem is grounded in the factual, verifiable regulations of a U.S. government healthcare program. It is a problem of applied logic and rule-following, not natural science, but is sound within its domain.\n-   **Well-Posed:** The problem is well-posed. It provides all necessary information: the structure of the benefit, the sequence of events, and a clear question. It asks for the outcome based on the \"foundational structure,\" implying a logical deduction from the given rules is required.\n-   **Objective:** The language is precise and unbiased.\n\nThe problem does not violate any of the invalidity criteria. It is a valid, solvable problem based on a defined set of rules.\n\n### Step 3: Derivation of the Solution\nThe core principle of the MHB is that its benefit periods are used sequentially and cannot be reset or paused.\n\n1.  **Initial State:** The patient elects the MHB, which initiates the first of the two `$90$`-day benefit periods. Let us denote the sequence of available periods as {$P_1$, $P_2$, $P_3$, $P_4$, ...}, where $P_1$ is the first `$90$`-day period, $P_2$ is the second `$90$`-day period, and $P_3, P_4, ...$ are the subsequent `$60$`-day periods. Upon the first election, the patient enters $P_1$.\n\n2.  **Use and Revocation:** The patient uses approximately `$60$` days of $P_1$. A benefit period, once started, is considered \"in use.\" The act of revocation is a formal termination of the benefit. A critical rule of the MHB is that when a patient revokes the benefit, they forfeit any remaining days in the current benefit period. In this case, the patient was in the first `$90$`-day period. By revoking, they lose the remaining `$\\approx 30$` days of that period. The period $P_1$ is now considered fully expended from the perspective of the patient's lifetime benefit sequence.\n\n3.  **Re-election:** The patient re-elects the MHB after `$3$` months. Re-election requires a new certification of terminal illness but allows the patient to resume hospice care. Since the benefit periods are sequential, the patient must begin with the next available period in their sequence.\n\n4.  **Determining the Next Period:** The patient has already used and completed their eligibility for the first benefit period, $P_1$. Therefore, the next available period in the sequence is the second benefit period, $P_2$, which is the second `$90$`-day period.\n\n**Conclusion:** Upon re-election, the patient starts the second `$90$`-day benefit period.\n\n### Option-by-Option Analysis\n\n-   **A. Upon re-election, the patient resumes the unused days of the first $90$-day benefit period and completes the remaining portion before moving to the second $90$-day period.**\n    -   This is incorrect. The regulations do not allow for the \"pausing\" and \"resuming\" of a benefit period. Revocation results in the forfeiture of the remaining days in the active period. The patient used approximately `$60$` days, and the remaining days of the first `$90$`-day period are lost.\n    -   **Verdict: Incorrect.**\n\n-   **B. Upon re-election, the patient begins the second $90$-day benefit period because the first $90$-day period was consumed by the initial election even though it was only partially used.**\n    -   This is correct. It accurately reflects the rules. The first `$90$`-day period was entered and is therefore considered \"consumed\" or \"used.\" The patient's revocation forfeited the remaining days. Upon re-electing, the patient progresses to the next period in the established sequence, which is the second `$90$`-day period.\n    -   **Verdict: Correct.**\n\n-   **C. Revocation resets the MHB entirely, allowing the patient to start over at the first $90$-day benefit period upon re-election.**\n    -   This is incorrect. The benefit periods are tracked over a patient's lifetime. A revocation does not erase the history of benefit use. Allowing a reset would create a loophole to repeatedly access the initial, longer benefit periods, which contradicts the design of the benefit.\n    -   **Verdict: Incorrect.**\n\n-   **D. The patient must wait for the remaining days of the first $90$-day period to elapse (outside hospice) before re-electing, at which point they start the second $90$-day period.**\n    -   This is incorrect. There is no mandatory waiting period after a revocation. A patient can re-elect the benefit at any time, provided they meet the clinical eligibility criteria (e.g., certification of a terminal prognosis). The `$3$`-month interval in the problem is part of the patient's story but not a regulatory requirement for re-election.\n    -   **Verdict: Incorrect.**\n\n-   **E. Upon re-election, the patient skips directly to the $60$-day periods because any revocation automatically bypasses the second $90$-day period.**\n    -   This is incorrect. The progression through benefit periods is strictly sequential. There is no rule that penalizes a patient for revoking by forcing them to skip the second `$90$`-day period. After using the first `$90$`-day period, the next available period is the second `$90$`-day period.\n    -   **Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}